How many stocks in xbi
Index Characteristics as of Apr 18 2022
| Est. 3-5 Year EPS Growth | Number of Holdings | Price/Earnings Ratio FY1 |
|---|---|---|
| -9.43% | 156 | 12.22 |
What stocks are in the XBI ETF?
Top 10 Holdings (8.60% of Total Assets)
| Name | Symbol | % Assets |
|---|---|---|
| Intellia Therapeutics Inc | NTLA | 1.18% |
| Editas Medicine Inc | EDIT | 0.94% |
| Anavex Life Sciences Corp | AVXL | 0.92% |
| Beam Therapeutics Inc | BEAM | 0.90% |
What does XBI consist of?
XBI focuses exclusively on American stocks, and primarily consists of mid cap and small cap securities. XBI’s portfolio is somewhat limited, though the equal-weighted methodology of the underlying index ensures that assets are balanced across all components.
What stocks make up IBB?
Top 25 Holdings
| Company | Symbol | Total Net Assets |
|---|---|---|
| Vertex Pharmaceuticals Inc. | VRTX | 5.50% |
| Illumina Inc. | ILMN | 4.36% |
| Moderna Inc. | MRNA | 4.25% |
| IQVIA Holdings Inc. | IQV | 4.11% |
What is the difference between IBB and XBI?
XBI is an equal-weight ETF, whereas IBB is cap weighted. That gives XBI a potential performance advantage when smaller biotech stocks are surging, but it also makes the ETF more volatile than its cap-weighted peer. XBI’s three-year annualized volatility is nearly 800 basis points higher than that of IBB.
Is Xbi a good investment?
For someone looking for broad-based exposure, including a large allocation to smaller, not-yet-profitable biotech companies, XBI is one of the best choices. Someone seeking more exposure to established, profitable, lower-risk biotech majors might better pass on XBI.
Why is Xbi stock dropping?
The XBI Index has had an accumulated collapse in the last year of approximately 50%. It is a historic fall because it had never suffered such a collapse before. Excessive growth during 2020 and early 2021, along with uncertainty about a possible interest rate hike scenario, could be behind this sharp decline.
What is the best genomic ETF?
Here are the seven best biotech ETFs to buy:
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
- ARK Genomic Revolution ETF (ARKG)
- First Trust NYSE Arca Biotechnology ETF (FBT)
- iShares Genomics Immunology and Healthcare ETF (IDNA)
- Invesco Dynamic BioTech & Genome ETF (PBE)
Is IBB a good stock to buy?
IShares Biotechnology ETF holds a Zacks ETF Rank of 1 (Strong Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IBB is a great option for investors seeking exposure to the Health Care ETFs segment of the market.
Is IBB a buy?
IBB has traded between $145.27 and $176.21 in this past 52-week period. The fund has a beta of 0.86 and standard deviation of 25.51% for the trailing three-year period, which makes IBB a high risk choice in this particular space. With about 270 holdings, it effectively diversifies company-specific risk.
Does IBB pay a dividend?
IBB Dividend Information
IBB has a dividend yield of 0.14% and paid $0.19 per share in the past year. The dividend is paid every three months and the last ex-dividend date was Mar 24, 2022.
What is the IBB ETF?
The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.